Key result
Thiolated chitosan nanoparticles boost ticagrelor bioavailability ~13% over standard chitosan nanoparticles.
Why the study?
Nanoparticles containing biodegradable polymers are promising for controlled oral delivery, but enhancing oral bioavailability of ticagrelor remains a challenge.
Does a thiolated chitosan nanoparticle formulation of ticagrelor improve oral bioavailability compared to chitosan nanoparticles in an in-vivo model?
Does a thiolated chitosan nanoparticle formulation of ticagrelor improve oral bioavailability compared to chitosan nanoparticles in an in-vivo model?
Absolute Event Rate: 494.96% vs 438.73%
p-value: p=< .05
Thiolated chitosan nanoparticles of ticagrelor significantly improve its oral bioavailability compared to standard chitosan nanoparticles in an in-vivo model.
Mucoadhesive TCNPs may enhance oral TG delivery; leaves open clinical translation pending in vivo and human studies.
The current study was aimed to design a thiolated chitosan (TC) based mucoadhesive nanoparticle (NP) formulation for enhancing the oral bioavailability of an anti-coagulant, Ticagrelor (TG). Nanoparticles (NPs) containing naturally occurring biodegradable polymers have been revealed as promising carriers for the controlled delivery of various therapeutic agents through the oral route. Ionic gelation technique was adopted to prepare thiolated chitosan nanoparticles of TG (TCNPs/TG) and chitosan (CH) nanoparticles of TG (CHNPs/TG) by varying the concentration of polymers with respect to TG and cross-linker i.e. tripolyphosphate (TPP). The prepared CHNPs/TG and TCNPs/TG were subjected to assessment for their particle size, the zeta potential, shape and morphology along with loading capacity (LC) and entrapment efficiency (EE). Formed TCNPs/TG showed a particle size of 190.3 nm, zeta potential of 16 mv along with the polydispersity index (PDI) of 0.375 as compared to CHNPs/TG, displaying particle size of 147.3 nm, zeta potential of 22.6 mv and PDI of 0.364. Likewise, during Fourier transform infrared spectroscopy (FTIR) analysis, the emergence of a characteristic peak at 2495 cm −1 in TC, has confirmed the successful modification of CH. Moreover, in-vitro drug release studies have disclosed a good sustained release behavior of the drug, both from CHNPs/TG and TCNPs/TG. However, the in-vivo pharmacokinetics have illustrated the superiority ( p < .05) of the TCNPs/TG (494.96 ng/mL) over the CHNPs/TG (438.73 ng/mL) in terms of bioavailability. Ultimately, the findings have indicated that TCNPs/TG might help to improve the oral bioavailability of TG and hence, its therapeutic effects.
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2022) studied this question. Thiolated chitosan nanoparticles of ticagrelor (TCNPs/TG) vs. Chitosan nanoparticles of ticagrelor (CHNPs/TG) was evaluated on Bioavailability (in-vivo pharmacokinetics) (p=< .05). Thiolated chitosan nanoparticles of ticagrelor demonstrated superior in-vivo bioavailability compared to chitosan nanoparticles (494.96 ng/mL vs 438.73 ng/mL, p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: